{"brief_title": "Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)", "brief_summary": "To evaluate the effect of application of Dinitrochlorobenzene (DNCB) on the number, morphology, and antigen expression of epidermal Langerhans cells in AIDS and AIDS related complex (ARC) patients.", "condition": ["HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Dinitrochlorobenzene"], "criteria": "Inclusion Criteria Patients must have the following: - Stage III or IV HIV infection. - Provide informed consent. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Kaposi's sarcoma lesions in the proposed treatment sites. - Liable to require radiation or chemotherapy during the course of the study. - Not likely to survive the length of the study. - Obvious ultra-violet-irradiated skin damage in the treatment areas and anyone with recent UV exposure or likely to have such exposure (e.g.: - holiday tans obtained in Hawaii, members of UV box tanning salons, etc.) Allergy to lidocaine. Concurrent Medication: Excluded: - Other Immunomodulators. Concurrent Treatment: Excluded: - Radiation. Patients with the following are excluded: - Kaposi's sarcoma lesions in the proposed treatment sites. - Liable to require radiation or chemotherapy during the course of the study. - Not likely to survive the length of the study. - Obvious ultra-violet-irradiated skin damage in the treatment areas. - Allergy to lidocaine. Prior Medication: Excluded: - Prior DNCB therapy.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "55 Years", "healthy_volunteers": "No", "keyword": "AIDS-Related Complex", "mesh_term": ["HIV Infections"], "id": "NCT00002031"}